Valsartan may increase the hypotensive activities of Tibolone. Heparin may increase the hyperkalemic activities of Valsartan. The metabolism of Ondansetron can be decreased when combined with Valsartan. The therapeutic efficacy of Valsartan can be decreased when used in combination with Acemetacin. The metabolism of Promazine can be decreased when combined with Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Serrapeptase. The metabolism of Atazanavir can be decreased when combined with Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Mycophenolic acid. The risk or severity of adverse effects can be increased when Valsartan is combined with Triamterene. The risk or severity of adverse effects can be increased when Valsartan is combined with Kebuzone. Bemiparin may increase the hyperkalemic activities of Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Candesartan cilexetil. The metabolism of Alosetron can be decreased when combined with Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Chlorthalidone. The risk or severity of adverse effects can be increased when Valsartan is combined with Etacrynic acid. The risk or severity of adverse effects can be increased when Valsartan is combined with Atenolol. Valsartan may increase the hypotensive activities of BQ-123. The risk or severity of adverse effects can be increased when Valsartan is combined with Pirfenidone. The risk or severity of adverse effects can be increased when Valsartan is combined with Empagliflozin. The risk or severity of adverse effects can be increased when Valsartan is combined with Enalapril. The risk or severity of adverse effects can be increased when Valsartan is combined with Quinapril. The metabolism of Donepezil can be decreased when combined with Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Diltiazem. The metabolism of Gliclazide can be decreased when combined with Valsartan. Moxonidine may increase the hypotensive activities of Valsartan. The metabolism of Valsartan can be decreased when combined with Sorafenib. The metabolism of Idarubicin can be decreased when combined with Valsartan. The metabolism of Valsartan can be decreased when combined with Fluconazole. The risk or severity of adverse effects can be increased when Pipamperone is combined with Valsartan. Valsartan may increase the hypotensive activities of Guanethidine. The risk or severity of adverse effects can be increased when Valsartan is combined with Etanercept. The metabolism of Rupatadine can be decreased when combined with Valsartan. The metabolism of Seratrodast can be decreased when combined with Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Tranilast. The metabolism of Nevirapine can be decreased when combined with Valsartan. The metabolism of Histamine can be decreased when combined with Valsartan. The metabolism of Zileuton can be decreased when combined with Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Reserpine. The risk or severity of adverse effects can be increased when Valsartan is combined with Isoxsuprine. The risk or severity of adverse effects can be increased when Valsartan is combined with Resveratrol. Sildenafil may increase the antihypertensive activities of Valsartan. The risk or severity of adverse effects can be increased when Thioridazine is combined with Valsartan. Valsartan may increase the hypotensive activities of Celiprolol. Reviparin may increase the hyperkalemic activities of Valsartan. The metabolism of Methoxyflurane can be decreased when combined with Valsartan. Tranylcypromine may increase the hypotensive activities of Valsartan. The metabolism of Amprenavir can be decreased when combined with Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Irbesartan. The metabolism of Valsartan can be decreased when combined with Lovastatin. The metabolism of Zopiclone can be decreased when combined with Valsartan. The metabolism of Diazepam can be decreased when combined with Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Naftifine. Yohimbine may decrease the antihypertensive activities of Valsartan. Valsartan may increase the hypotensive activities of Mibefradil. The risk or severity of adverse effects can be increased when Valsartan is combined with Bisoprolol. The metabolism of Ketamine can be decreased when combined with Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Timolol. The risk or severity of adverse effects can be increased when Valsartan is combined with Indobufen. Valsartan may increase the arrhythmogenic activities of Ciprofloxacin. Nadroparin may increase the hyperkalemic activities of Valsartan. The metabolism of Diclofenac can be decreased when combined with Valsartan. The metabolism of Olodaterol can be decreased when combined with Valsartan. The metabolism of Halothane can be decreased when combined with Valsartan. The metabolism of Dextromethorphan can be decreased when combined with Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Guanfacine. The risk or severity of adverse effects can be increased when Clofarabine is combined with Valsartan. The metabolism of Bupropion can be decreased when combined with Valsartan. Indoramin may increase the hypotensive activities of Valsartan. Iproclozide may increase the hypotensive activities of Valsartan. Rasagiline may increase the hypotensive activities of Valsartan. The metabolism of Fluoxetine can be decreased when combined with Valsartan. The metabolism of Trimethadione can be decreased when combined with Valsartan. The metabolism of Flunarizine can be decreased when combined with Valsartan. The metabolism of Glyburide can be decreased when combined with Valsartan. The risk or severity of adverse effects can be increased when Ropinirole is combined with Valsartan. The metabolism of Ketobemidone can be decreased when combined with Valsartan. The metabolism of Bexarotene can be decreased when combined with Valsartan. Valsartan may increase the hypotensive activities of Metyrosine. The metabolism of Methadone can be decreased when combined with Valsartan. The metabolism of Imatinib can be decreased when combined with Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Tizanidine. The metabolism of Lumiracoxib can be decreased when combined with Valsartan. Rilmenidine may increase the hypotensive activities of Valsartan. The metabolism of Troglitazone can be decreased when combined with Valsartan. The metabolism of Dopamine can be decreased when combined with Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Enalaprilat. The risk or severity of adverse effects can be increased when Clomipramine is combined with Valsartan. The metabolism of Theophylline can be decreased when combined with Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Chloroquine. The risk or severity of adverse effects can be increased when Valsartan is combined with Sulfasalazine. Valsartan may increase the hypotensive activities of Unoprostone. Quinine may increase the hypotensive activities of Valsartan. The metabolism of Estradiol can be decreased when combined with Valsartan. The metabolism of Valdecoxib can be decreased when combined with Valsartan. Ardeparin may increase the hyperkalemic activities of Valsartan. The metabolism of Acenocoumarol can be decreased when combined with Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Masoprocol. The risk or severity of adverse effects can be increased when Valsartan is combined with Penbutolol. The serum concentration of Valsartan can be increased when it is combined with Eltrombopag. The risk or severity of adverse effects can be increased when Valsartan is combined with Isosorbide Mononitrate. The metabolism of Tolterodine can be decreased when combined with Valsartan. The metabolism of Valsartan can be decreased when combined with Fluvoxamine. The risk or severity of adverse effects can be increased when Valsartan is combined with Temocapril. The metabolism of Rosuvastatin can be decreased when combined with Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Meclofenamic acid. Valsartan may increase the hyperkalemic activities of Drospirenone. Ketanserin may increase the hypotensive activities of Valsartan. The metabolism of Valsartan can be decreased when combined with Fluorouracil. The metabolism of Glipizide can be decreased when combined with Valsartan. Brimonidine may increase the antihypertensive activities of Valsartan. The metabolism of Trimipramine can be decreased when combined with Valsartan. Tinzaparin may increase the hyperkalemic activities of Valsartan. Valsartan may increase the hypotensive activities of Efonidipine. The serum concentration of Carvedilol can be increased when it is combined with Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Bufexamac. The risk or severity of adverse effects can be increased when Valsartan is combined with Methyclothiazide. Udenafil may increase the antihypertensive activities of Valsartan. The metabolism of Lornoxicam can be decreased when combined with Valsartan. Phenoxypropazine may increase the hypotensive activities of Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Carprofen. The risk or severity of adverse effects can be increased when Valsartan is combined with Azapropazone. The metabolism of Antipyrine can be decreased when combined with Valsartan. The metabolism of Phenacetin can be decreased when combined with Valsartan. Isocarboxazid may increase the hypotensive activities of Valsartan. The metabolism of Sitaxentan can be decreased when combined with Valsartan. The risk or severity of adverse effects can be increased when Valsartan is combined with Moexipril. The risk or severity of adverse effects can be increased when Fimasartan is combined with Valsartan. The metabolism of Warfarin can be decreased when combined with Valsartan. The metabolism of Valsartan can be decreased when combined with Cholecalciferol. The risk or severity of adverse effects can be increased when Valsartan is combined with Methyldopa.